Last reviewed · How we verify
AD-223C
AD-223C is a small molecule that targets the PD-1 receptor.
AD-223C is a small molecule that targets the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | AD-223C |
|---|---|
| Sponsor | Addpharma Inc. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, AD-223C prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD-223C CI brief — competitive landscape report
- AD-223C updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI